Novartis antitrust lawyer sceptical of innovation review in pharma mergers

Charles McConnell

27 October 2017

Novartis antitrust lawyer sceptical of innovation review in pharma mergers

The head of Novartis’ antitrust legal team yesterday said innovation considerations while reviewing mergers in the pharmaceutical industry may be a solution in search of a problem.